- Featured Highlights Press Press ReleasesImmunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial of ITI-3000 in Patients Diagnosed with Merkel Cell Carcinoma ITI-3000 Demonstrated a Favorable Safety and Tolerability Profile Patients showedRead more
ITI Doses First Patient in its Phase 1 Clinical Trial of ITI-1001
Featured Highlights Press Press ReleasesImmunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme -Top-Line Data Expected in the Second Quarter ofRead moreWashington Business Journal interviews CEO, Dr. William Hearl
Articles Featured Highlights PressJuly 14, 2023 Immunomic Therapeutics is highlighted in Washington Business Journal's cover story, “Life sciences funding is tough, but there are still avenues to money.” WBJ talks about how aRead more- Featured Highlights Press Press ReleasesMarch 06, 2023 09:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today thatRead more
Immunomic Therapeutics to Present at Biotech Showcase 2023
Featured Highlights Press Press ReleasesJanuary 04, 2023 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today thatRead more- Featured Highlights Press Press ReleasesVaccine exclusively delivered with the PharmaJet Stratis® Needle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, a company that engineers precision delivery systems that overcomeRead more
ITI Receives FDA Fast Track Designation for ITI-3000
Featured Highlights Press Press ReleasesNovember 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announcedRead moreITI Announces Presentation on Nucleic Acid-Based UNITE® Vaccine Platform at Vaccines Summit 2022
Featured Highlights Press Press ReleasesOctober 10, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced todayRead moreITI Announces the Appointment of Frances Harrison as Sr. VP, Regulatory Affairs
Featured Highlights Press Press ReleasesImmunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs September 06, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”),Read more- Featured Highlights Press Press ReleasesImmunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma -Top line data expected in second half ofRead more
BioBuzz Interview with Brian Stamper, ITI’s VP of Cell Therapy
Articles Blog Featured Highlights Presshttps://biobuzz.io/brian-stamper-appointed-vice-president-cell-therapy-operations-at-immunomic-therapeutics/Read moreImmunomic Therapeutics Appoints Vice President, Cell Therapy
Featured Highlights Press Press ReleasesJune 07, 2022 10:24 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleicRead more